Recently, Shandong Xinbo Drug Research Co., Ltd. has been successfully selected into the provincial-level 2026 scenario capability list in Shandong Province, thanks to its core technical strength, comprehensive service system, and outstanding innovation ability in the field of preclinical drug safety evaluation!

Demonstrate Shandong Xinbo's leading position and core competitiveness in the biopharmaceutical R&D service sector, and establish it as a benchmark enterprise for scenario innovation in the field of life and health.

Deeply cultivating the field of safety assessment, laying a solid foundation for innovation
As a national high-tech enterprise, Shandong Provincial Enterprise Technology Center, and specialized, refined, unique, and innovative small and medium-sized enterprise, Shandong Xinbo has been focusing on the core field of preclinical drug safety evaluation since its establishment in 2010. It has established a one-stop scientific research service system encompassing pharmacodynamics, toxicology, drug analysis, pathological testing, and medical device evaluation.
The company has established two major laboratories in Jinan and Linyi, with over 20,000 square meters of experimental space that meets international standards. Equipped with over 800 high-end precision instruments, it strictly adheres to NMPA, FDA, and GLP standards and is capable of conducting comprehensive toxicology research in nine major areas, covering various types of drug evaluations such as small molecules, biological macromolecules, vaccines, traditional Chinese medicine, and cell and gene therapy products.

Being selected into the provincial list, we will continue to write a new chapter of development
The successful inclusion in the provincial-level scenario capability list of Shandong Province is a high recognition of the company's technical capabilities, innovation level, and industry contributions. It also represents a significant opportunity for the company to integrate into the province's new productive forces development layout and empower the high-quality development of the biomedical industry.

In the future, Shandong Xinbo will leverage this momentum to continuously increase its R&D investment, refine its core technologies, and improve its service ecosystem. With stronger capabilities and more professional services, it aims to assist more innovative drugs in transitioning from the laboratory to clinical trials, contributing Xinbo's strength to building Shandong into a nationally leading hub for biomedical innovation!